Big medtechs’ efficiency starts to recover from Covid
Orthopaedics and cardiology groups start to improve in terms of sales per employee, but Covid test makers do better still.
Philips draws a line under its sleep nightmare
The group has finally revalued its troubled sleep franchise. So what now?
Medtech research spending set to slow in 2022
And some diagnostics groups are forecast to actually cut R&D outlay this year as the pandemic eases.
Up-and-down test sales and a bigger Medtronic: medtech in 2028
Medtronic, Siemens and Stryker are all expected to seize greater market share, while Roche slides down the rankings.
Diagnostics beat implants in the race to market
Roche had the most innovative approvals over the last five years – but took second place in terms of speed.
Device makers buy big
Whether sitting on a pile of cash or guarding against growing pressures, acquisitions are the answer.
A bad year to be an American medtech
Big-cap device makers on European exchanges did nicely in 2021, whereas their US-listed brethren had a harder time.
Covid-19 scrambles big medtech’s spending
Roche, its coffers full from coronavirus test sales, ups its research spending – but Baxter cuts back.
Healthineers scores big in the third quarter
Diagnostics companies enjoy notable uplift in sales; elsewhere, spinouts could shape the future.